ATE106249T1 - Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. - Google Patents

Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.

Info

Publication number
ATE106249T1
ATE106249T1 AT88310372T AT88310372T ATE106249T1 AT E106249 T1 ATE106249 T1 AT E106249T1 AT 88310372 T AT88310372 T AT 88310372T AT 88310372 T AT88310372 T AT 88310372T AT E106249 T1 ATE106249 T1 AT E106249T1
Authority
AT
Austria
Prior art keywords
immunogenic potential
immunoglobulin
improved pharmacokinetics
modified immunoglobulins
reduced immunogenic
Prior art date
Application number
AT88310372T
Other languages
English (en)
Inventor
Roberto Cesare Fagnani
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Application granted granted Critical
Publication of ATE106249T1 publication Critical patent/ATE106249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88310372T 1987-11-05 1988-11-03 Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. ATE106249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11815087A 1987-11-05 1987-11-05

Publications (1)

Publication Number Publication Date
ATE106249T1 true ATE106249T1 (de) 1994-06-15

Family

ID=22376776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88310372T ATE106249T1 (de) 1987-11-05 1988-11-03 Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.

Country Status (5)

Country Link
EP (1) EP0315456B1 (de)
JP (1) JPH01163133A (de)
AT (1) ATE106249T1 (de)
AU (1) AU610946B2 (de)
DE (1) DE3889853D1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US6245879B1 (en) * 1999-01-29 2001-06-12 Shell Oil Company Purification of 1,3-propanediol in carbonyl-containing stream
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ITMI20010347A1 (it) 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
AU2004261941B2 (en) 2003-07-25 2008-04-10 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
CA2552750C (en) 2004-01-07 2021-11-09 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
EP2311876A3 (de) 2005-07-28 2011-04-27 Novartis AG M-CSF-spezifischer monoklonaler Antikörper und Verwendungen davon
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
EP2010569A4 (de) 2006-03-20 2009-09-09 Xoma Technology Ltd Für gastrin spezifische humane antikörper, materialien und methoden
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
KR20090016596A (ko) 2006-05-19 2009-02-16 글리코파이, 인크. 에리트로포이에틴 조성물
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
KR101433544B1 (ko) 2006-08-18 2014-08-27 노바르티스 아게 Ｐｒｌｒ 특이적 항체 및 그 용도
US8043829B2 (en) 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
AU2007329307B2 (en) 2006-12-07 2012-08-02 Novartis Ag Antagonist antibodies against EphB3
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP5643643B2 (ja) 2007-07-26 2014-12-17 アムジエン・インコーポレーテツド 変性レシチン−コレステロールアシルトランスフェラーゼ酵素
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
ES2441941T3 (es) 2008-10-15 2014-02-07 Baxter Healthcare Sa Pegilación de factores de coagulación sanguínea recombinantes en presencia de anticuerpos enlazados
CA2889453C (en) 2009-03-20 2018-11-06 Amgen Inc. Carrier immunoglobulins and uses thereof
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
EP2443145A1 (de) 2009-06-17 2012-04-25 Amgen, Inc Chimäre fgf19-polypeptide und ihreverwendung
JP2012530498A (ja) 2009-06-19 2012-12-06 メディミューン，エルエルシー プロテアーゼバリアント
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
JP2014526441A (ja) 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
JP6463331B2 (ja) 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
EP3197915A4 (de) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanisierte anti-hepcidin-antikörper und verwendungen davon
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CA3131705A1 (en) 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate

Also Published As

Publication number Publication date
AU2475588A (en) 1989-05-18
AU610946B2 (en) 1991-05-30
EP0315456A3 (en) 1990-03-28
JPH01163133A (ja) 1989-06-27
DE3889853D1 (de) 1994-07-07
EP0315456B1 (de) 1994-06-01
EP0315456A2 (de) 1989-05-10

Similar Documents

Publication Publication Date Title
ATE106249T1 (de) Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
EP0527821A4 (en) Oxidation resistant thrombomodulin analogs
ES2095847T3 (es) Desnaturalizacion oxidativa de analitos proteicos.
DE69311278D1 (de) Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
ATE108799T1 (de) Konjugate von in position c-3 eine detergens- kette enthaltenden vinca-derivaten.
ATE259878T1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
ATE124266T1 (de) Antikörper-konjugate mit zwei oder mehr kovalent vernetzten fc-regionen.
DE3788229D1 (de) Verfahren zur isolierung von ca 125-antigen.
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
ATE16603T1 (de) Immunoglobulinkonjugate.
SE7608174L (sv) Forfarande for framstellning av antiserum
NO854581L (no) Fremgangsmaate for fremstilling av en vannloeselig polymer.
KR860006542A (ko) 안정화된 효소결합체 조성물
ATE168115T1 (de) In lösung bringen von proteinen in aktiver form
DK0529019T3 (da) Nematodevaccine
SE8602523D0 (sv) 2-alkyl- eller -aralkyltio-1-cykloalken-1-karboxamider och deras sulfoxider, sett for deras framstellning och deras anvendning for syntes av tri- och 4,5-tetrametylen-4-isotiazolin-3-oner
SE9300139D0 (sv) Manufacture of a new drug
DE3884315D1 (de) Verwendung von Epithioderivaten ungesättigter Kohlenstoffverbindungen als Weichmacher sowie diese enthaltende Dichtungsmassen.
SE8504228L (sv) Tumordodande emne
SE8002602L (sv) Diagnostiskt forfarande

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties